Avacincaptad pegol vs Pozelimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: Complement C5 · full Age-Related Macular Degeneration pipeline

Avacincaptad pegol · Izervay

Marketed by Astellas Pharma

Approved in Age-Related Macular DegenerationRNA aptamer
Reliable signal

NCT04435366 · Phase 3 · completed

This was a randomized, double-blind (participant, evaluating investigator, reading center, and sponsor masked), sham-controlled, parallel-group Phase 3 trial with 448 participants randomized to avacincaptad pegol or sham. The hard primary endpoint of geographic atrophy growth rate on fundus autofluorescence was met: avacincaptad pegol slowed GA enlargement compared with sham at Month 12 (LS mean 0.336 vs 0.392 mm/year; difference 0.056; 95% CI 0.016–0.096; p=0.0064), and both Month 24 co-primary comparisons also favored avacincaptad pegol. Secondary visual acuity and visual-function questionnaire endpoints did not show a significant benefit, but the primary structural endpoint was statistically significant.

Next expected readout: June 2027 · NCT06970665 (registry estimate)

Reported efficacy

The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12 (Baseline to month 12); The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24 (Baseline to month 24): 12-month geographic-atrophy growth: 0.336 vs 0.392 mm/year for avacincaptad pegol vs sham; difference 0.056 mm/year (95% CI 0.016 to 0.096; p=0.0064). 24-month geographic-atrophy growth: 2.23 vs 2.59 mm²/year for monthly avacincaptad pegol vs sham; difference 0.362 mm²/year (95% CI 0.066 to 0.657; p=0.0165). (met)

Result source: NCT04435366

Pozelimab · Veopoz

Marketed by Regeneron Pharmaceuticals

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2028 · NCT07230834 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pozelimab: no structured comparison results are available for Age-Related Macular Degeneration.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Avacincaptad pegol

GA Area Growth 0.336 vs 0.392 placebo per year @ 52wk
absolute value · per year
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
show 2 more results
2.23 vs 2.59 placebo per year @ 104wk
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
2.1 vs 2.59 placebo per year @ 104wk
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
BCVA Change Letters -7.31 vs -6.48 placebo score @ 104wk
absolute change · score
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
LL-BCVA Change Letters -10.58 vs -9.1 placebo score @ 104wk
absolute change · score
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
VFQ-25 Composite -7.735 vs -7.023 placebo score @ 104wk
absolute change · score
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
Time to Persistent Vision Loss 17.02 vs 13.93 placebo months
time to event · months
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
GA Area Change Mm2 0.321 vs 0.402 placebo mm @ 52wk4 mg
absolute change · mm
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
show 1 more result
0.292 vs 0.402 placebo mm @ 52wk2 mg
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
BCVA Change Letters -3.79 vs -9.29 placebo ETDRS Letters @ 52wk4 mg
absolute change · ETDRS Letters
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
show 1 more result
-7.9 vs -9.29 placebo ETDRS Letters @ 52wk2 mg
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
LL-BCVA Change Letters 1.53 vs -1.41 placebo ETDRS Letters @ 52wk4 mg
absolute change · ETDRS Letters
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
show 1 more result
-1.03 vs -1.41 placebo ETDRS Letters @ 52wk2 mg
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
Available safety results

Avacincaptad pegol

Dropout rate
11.1%Avacincaptad Pegol
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
show 11 more results
—Avacincaptad Pegol Only (12 to 24
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
—Avacincaptad Pegol Only (up to 12
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
—Avacincaptad Pegol and Sham
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
—Avacincaptad Pegol and Sham Only (
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
44.6%4 mg
NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
28.6%2 mg
NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
28%2 mg
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
15.4%1 mg
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
—EM
NCT05536297 · Phase 3 · registry result, not featured evidence
—EM
NCT05536297 · Phase 3 · registry result, not featured evidence
16.4%EM
NCT05536297 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
1.3%Avacincaptad Pegol
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
show 11 more results
—Avacincaptad Pegol Only (12 to 24
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
—Avacincaptad Pegol Only (up to 12
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
—Avacincaptad Pegol and Sham
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
—Avacincaptad Pegol and Sham Only (
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
2.4%4 mg
NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
2.4%2 mg
NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
0%2 mg
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
0%1 mg
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
—EM
NCT05536297 · Phase 3 · registry result, not featured evidence
—EM
NCT05536297 · Phase 3 · registry result, not featured evidence
4.6%EM
NCT05536297 · Phase 3 · registry result, not featured evidence
Serious AEs
—Avacincaptad Pegol
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
show 11 more results
18.8%Avacincaptad Pegol Only (12 to 24
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
13.8%Avacincaptad Pegol Only (up to 12
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
—Avacincaptad Pegol and Sham
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
17.2%Avacincaptad Pegol and Sham Only (
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
25.3%4 mg
NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
19%2 mg
NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
16%2 mg
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
11.5%1 mg
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
21.9%EM
NCT05536297 · Phase 3 · registry result, not featured evidence
21.3%EM
NCT05536297 · Phase 3 · registry result, not featured evidence
15.9%EM
NCT05536297 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
conjunctival haemorrhage 14.6% (placebo 2.5%)
choroidal neovascularisation 11.5% (placebo 9.4%)
covid-19 11.5% (placebo 12.8%)
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
show 9 more results
conjunctival haemorrhage 13.8% (placebo 2.5%)
intraocular pressure increased 9.8% (placebo 0.5%)
choroidal neovascularisation 9.3% (placebo 9.4%)
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
covid-19 15.1% (placebo 12.8%)
conjunctival haemorrhage 9.7% (placebo 2.5%)
choroidal neovascularisation 8.6% (placebo 9.4%)
NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3
4 mg
conjunctival haemorrhage * 33.7% (placebo 14.3%)
intraocular pressure increased 22.9% (placebo 1.2%)
neovascular age-related macular degeneration* 13.3% (placebo 2.4%)
NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
2 mg
conjunctival haemorrhage * 21.4% (placebo 14.3%)
fall 19% (placebo 8.3%)
neovascular age-related macular degeneration* 16.7% (placebo 2.4%)
NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
2 mg
nasopharyngitis 12% (placebo 6%)
conjunctival haemorrhage * 8% (placebo 14.3%)
influenza 8% (placebo 1.2%)
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
1 mg
neovascular age-related macular degeneration* 11.5% (placebo 2.4%)
vitreous detachment* 11.5% (placebo 7.1%)
cataract* 7.7% (placebo 6%)
NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3
EM
choroidal neovascularisation 15.6%
fall 14.1%
intraocular pressure increased 14.1%
NCT05536297 · Phase 3 · registry result, not featured evidence
EM
cataract 16.4%
intraocular pressure increased 16.4%
conjunctival haemorrhage 9.8%
NCT05536297 · Phase 3 · registry result, not featured evidence
EM
intraocular pressure increased 13.9%
choroidal neovascularisation 13.2%
visual acuity reduced 11.9%
NCT05536297 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Avacincaptad pegol's landscape · Pozelimab's landscape